Skip to main navigation
Skip to search
Skip to main content
University of Nottingham Ningbo China Home
Home
Profiles
Research units
Research output
Projects
Prizes
Activities
Press/Media
Impacts
Student theses
Search by expertise, name or affiliation
View Scopus Profile
Dr Jun Xia
Director of Nottingham Ningbo GRADE Centre
School of Economics
Email
Jun.Xia
nottingham.edu
cn
h-index
4130
Scopus Citations
31
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2005
2025
Research activity per year
Overview
Fingerprint
Network
Projects
(19)
Research output
(101)
Prizes
(1)
Activities
(1)
Fingerprint
Dive into the research topics where Jun Xia is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Confidence Interval
100%
Schizophrenia
94%
Randomized Controlled Trial
58%
Risk Ratio
55%
Meta-analysis
43%
Systematic Meta-analysis
37%
Placebo
31%
Cochrane
30%
Adverse Events
29%
Risk of Bias
26%
Antipsychotics
26%
People with Schizophrenia
22%
Acupuncture
20%
MEDLINE
19%
Embase
18%
Severe Mental Illness
16%
China
15%
Cochrane Review
15%
Atypical Antipsychotics
14%
Network Meta-analysis
14%
Selection Criteria
13%
Quality of Life
13%
Relative Risk
13%
COVID-19
13%
Adverse Effects
13%
Pharmacological Intervention
13%
Psychoeducation
12%
Basal Insulin
12%
Cancer Pain
12%
Hydromorphone
12%
Attention Deficit Hyperactivity Disorder
12%
Type 2 Diabetes Mellitus (T2DM)
12%
Tinnitus
12%
Cochrane Systematic Review
12%
Acne
12%
Evidence-based Clinical Practice Guideline
12%
Review Authors
11%
Clinical Practice Guidelines
11%
Number-needed-to-treat
11%
Risperidone
11%
Inter-rater Reliability
10%
Search Methods
10%
Grading of Recommendations
9%
Assessment Development
9%
Evaluation Assessment
9%
Extracted Data
9%
Randomized Clinical Trial
9%
Mental States
9%
Tolerability
8%
Cognitive Behavioral Therapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
81%
Adverse Event
41%
Placebo
30%
Antipsychotic
20%
Typical Antipsychotic
19%
Atypical Antipsychotics
14%
Chemoradiation Therapy
12%
Cancer Pain
12%
Hydromorphone
12%
Tinnitus
12%
Risperidone
11%
Disease
10%
Number Needed to Treat
10%
Randomized Clinical Trial
10%
Symptom
10%
Tolerability
8%
Chemotherapy
8%
Cholinesterase Inhibitor
8%
Delirium
8%
Nasopharynx Carcinoma
8%
Non Insulin Dependent Diabetes Mellitus
8%
Attention Deficit Disorder
8%
Tripterygium wilfordii
8%
Ginkgo Biloba
8%
Sulfur
8%
Nicotinamide
8%
Azelaic Acid
8%
Salicylic Acid
8%
Acne
8%
Rheumatoid Arthritis
8%
Quetiapine
6%
Infection
6%
Group Trial
6%
Negative Syndrome
5%
Controlled Clinical Trial
5%
2 Hydroxyacid
5%
Overall Survival
5%
Clinical Trial
5%
Clozapine
5%
Medicine and Dentistry
Randomized Controlled Trial
53%
Systematic Review
51%
Meta-Analysis
24%
Auriculotherapy
20%
Adverse Event
15%
Typical Antipsychotic
13%
Network Meta-Analysis
12%
Acneiform Eruption
12%
Placebo
10%
Quality of Life
9%
Clinician
9%
Drug Therapy
9%
Adolescent
8%
Cognitive Behavioral Therapy
8%
Dance Therapy
8%
Attention Deficit Disorder
8%
Tripterygium wilfordii
8%
Chinese Herbal Medicine
8%
Salicylic Acid
8%
Sulfur
8%
Azelaic Acid
8%
Nicotinamide
8%
Pneumonia
8%
Hearing Impairment
8%
Neuropathic Pain
8%
Rheumatoid Arthritis
8%
COVID-19
8%
Maturity Onset Diabetes of the Young
8%
Sequela
8%
Infection
7%
Group Trial
6%
Symptom
5%
2 Hydroxyacid
5%
Topical Treatment
5%
